[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].

Abstract

Chronic administration of levodopa and benserazide (10 and 15 mg/kg, respectively) cause the development of dyskinesia in rats with model parkinsonian syndrome induced by injection of 6-hydroxydopamine in left substantia nigra. The chronic administration of these drugs together with amantadine (20 mg/kg) accelerates the onset of latency and increases the magnitude of dyskinesia. Chronic administration of levodopa and benserazide together with hemantane (10 mg/kg) slows down the development and decreases the magnitude of levodopa-induced abnormal involuntary movements as measured for limb, orolingual and rotatory movements.

• Authors: I G Kapitsa, E A Ivanova, A V Nepoklonov, I I Kokshenev, T A Voronina, E A Val'dman
• Journal: Eksperimental'naia i klinicheskaia farmakologiia (Eksp Klin Farmakol) Vol. 74 Issue 7 Pg. 9-12 ( 2011) ISSN: 0869-2092 [Print] Russia (Federation)
• PMID: 21894760 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• hemantane
• Levodopa
• Benserazide
• Oxidopamine
• Amantadine
• Adamantane

Topics

• Adamantane (administration & dosage, analogs & derivatives, therapeutic use)
• Amantadine (administration & dosage, adverse effects)
• Animals
• Behavior, Animal (drug effects)
• Benserazide (pharmacology)
• Disease Models, Animal
• Dyskinesia, Drug-Induced (drug therapy, physiopathology)
• Levodopa (administration & dosage, adverse effects)
• Male
• Oxidopamine (administration & dosage, adverse effects)
• Parkinsonian Disorders (chemically induced, drug therapy, physiopathology)
• Rats
• Substantia Nigra (drug effects)